Evidence map›Paper›PMID 34686719›Full record

ArticleScientific reports2021

Quantification of the spatial distribution of primary tumors in the lung to develop new prognostic biomarkers for locally advanced NSCLC.

Diem Vuong, Marta Bogowicz, Leonard Wee, Oliver Riesterer, Eugenia Vlaskou Badra, Louisa Abigail D'Cruz, Panagiotis Balermpas, Janita E van Timmeren, Simon Burgermeister, André Dekker and 8 more

Abstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Diem VuongDepartment of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. diem.vuong@usz.ch.
Marta BogowiczDepartment of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Leonard WeeDepartment of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands.
Oliver RiestererDepartment of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Eugenia Vlaskou BadraDepartment of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Louisa Abigail D'CruzStrahlentherapie und Onkologie, Universitätsklinikum Frankfurt, Frankfurt, Germany.
Panagiotis BalermpasDepartment of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Janita E van TimmerenDepartment of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Simon BurgermeisterDepartment of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
André DekkerDepartment of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands.
Dirk De RuysscherDepartment of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands.
Jan UnkelbachDepartment of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Sandra ThiersteinSwiss Group for Clinical Cancer Research (SAKK), Coordinating Center, Bern, Switzerland.
Eric I EbouletSwiss Group for Clinical Cancer Research (SAKK), Coordinating Center, Bern, Switzerland.
Solange PetersDepartment of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
Miklos PlessDepartment of Medical Oncology, Kantonsspital Winterthur, Winterthur, Switzerland.
Matthias GuckenbergerDepartment of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Stephanie Tanadini-LangDepartment of Radiation Oncology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.

Funding

Swiss National Science Foundation 310030_173303
6 · The paper itself

Abstract

The anatomical location and extent of primary lung tumors have shown prognostic value for overall survival (OS). However, its manual assessment is prone to interobserver variability. This study aims to use data driven identification of image characteristics for OS in locally advanced non-small cell lung cancer (NSCLC) patients. Five stage IIIA/IIIB NSCLC patient cohorts were retrospectively collected. Patients were treated either with radiochemotherapy (RCT): RCT1* (n = 107), RCT2 (n = 95), RCT3 (n = 37) or with surgery combined with radiotherapy or chemotherapy: S1* (n = 135), S2 (n = 55). Based on a deformable image registration (MIM Vista, 6.9.2.), an in-house developed software transferred each primary tumor to the CT scan of a reference patient while maintaining the original tumor shape. A frequency-weighted cumulative status map was created for both exploratory cohorts (indicated with an asterisk), where the spatial extent of the tumor was uni-labeled with 2 years OS. For the exploratory cohorts, a permutation test with random assignment of patient status was performed to identify regions with statistically significant worse OS, referred to as decreased survival areas (DSA). The minimal Euclidean distance between primary tumor to DSA was extracted from the independent cohorts (negative distance in case of overlap). To account for the tumor volume, the distance was scaled with the radius of the volume-equivalent sphere. For the S1 cohort, DSA were located at the right main bronchus whereas for the RCT1 cohort they further extended in cranio-caudal direction. In the independent cohorts, the model based on distance to DSA achieved performance: AUC

Indexed as

Biomarkers, TumorCarcinoma, Non-Small-Cell LungChemoradiotherapyHumansLungLung NeoplasmsMaleMiddle AgedNeoplasm StagingPrognosisRetrospective StudiesTumor BurdenBiomarkers, Tumor

Identifiers

PMID34686719
PMCPMC8536672

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.